胰十二指肠切除或全胰切除联合静脉切除术后抗凝实践与门静脉血栓风险:国际多中心队列研究
这项国际多中心队列研究纳入2018-2022年接受PD/TP联合静脉切除(VR)的972例患者,并匹配无VR队列。VR组30天、90天和1年PVT风险分别为5.1%、7.3%和11.6%,显著高于无VR组的1.0%、1.3%和2.6%(P<0.001)。术后治疗性抗凝降低30天PVT风险(OR 0.06,P<0.001),但未显著降低90天(P=0.075)或90天以上PVT风险(P=0.466);90天以上PVT最强预测因素为肿瘤复发(OR 3.96,P<0.001)。
要点
- PD/TP联合静脉切除显著增加门静脉血栓风险,1年累积风险达11.6%。
- 术后治疗性抗凝仅降低30天PVT风险,对90天及以后PVT无显著获益。
- 静脉切除类型和移植物材料影响90天内PVT风险,肿瘤复发预测90天以上PVT。
核心结论
- 静脉切除增加PD/TP术后门静脉血栓风险,技术因素影响90天内PVT,肿瘤相关因素影响90天以上PVT。
- 术后早期抗凝预防静脉切除后PVT的获益尚不明确。
研究设计与样本
- 国际多中心队列研究,纳入欧洲、美国、墨西哥、土耳其、澳大利亚、新西兰2018-2022年连续接受PD/TP联合静脉切除的患者972例。
- 另收集1:1年龄和性别匹配的无静脉切除PD/TP队列以评估无VR时PVT风险。
主要发现
- 静脉切除组30天、90天和1年PVT风险分别为5.1%、7.3%和11.6%,无VR组分别为1.0%、1.3%和2.6%(P<0.001)。
- 972例静脉切除患者中,259例(26.6%)接受住院期间治疗性抗凝,242例(25.0%)出院时接受治疗性抗凝。
- 90天PVT预测因素包括既往静脉血栓栓塞史(OR 2.67)、静脉切除类型(1-4型OR分别为2.29、6.28、6.90、23.75,P<0.001)和移植物材料(腹膜、自体静脉、尸体静脉、牛源和合成移植物OR分别为0.78、0.94、5.28、4.90、5.99,P<0.001)。
- 术后治疗性抗凝降低30天PVT风险(OR 0.06,P<0.001),但未显著降低90天(OR 0.06,P=0.075)或90天以上PVT风险(OR 1.23,P=0.466)。
- 90天以上PVT最强预测因素为肿瘤复发(OR 3.96,P<0.001)。
临床怎么用
- 对PD/TP联合静脉切除患者应警惕PVT风险,尤其在高类型静脉切除或使用特定移植物材料时。
- 术后早期治疗性抗凝可能降低30天PVT风险,但需权衡获益与出血风险,长期抗凝预防PVT证据不足。
- 90天以上PVT风险与肿瘤复发相关,随访中需关注肿瘤复发及PVT监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Assess anticoagulation practice and portal vein thrombosis (PVT) risk following pancreaticoduodenectomy (PD) or total pancreatectomy (TP) with venous resection (VR). BACKGROUND: Retrospective studies suggest an increased risk of PVT following PD/TP with VR. However, anticoagulation practice is variable and its efficacy at preventing PVT is unknown. METHODS: This multicentre cohort study (Europe, USA, Mexico, Turkey, Australia, New Zealand) included consecutive patients undergoing PD/TP with VR between 2018-2022. A 1:1 age and sex matched cohort undergoing PD/TP without VR was also collected to assess PVT risk without VR. RESULTS: Among 972 patients who underwent PD/TP with VR, 259 (26.6%) received inpatient therapeutic anticoagulation and 242 (25.0%) were discharged on therapeutic anticoagulation. Thirty-day, 90-day and one-year PVT risk following VR was 5.1%, 7.3%, and 11.6%, versus 1.0%, 1.3% and 2.6% in patients without VR (P<0.001). Predictors of 90-day PVT included prior history of venous thromboembolism (odds ratio [OR] 2.67), VR type (OR 2.29, 6.28, 6.90 and 23.75 for type 1-4 VR, P<0.001) and graft material (OR 0.78, 0.94, 5.28, 4.90 and 5.99 for peritoneal, autologous vein, cadaveric vein, bovine and synthetic grafts, P<0.001). Postoperative therapeutic anticoagulation reduced 30-day PVT risk (OR 0.06, P<0.001), but not 90-day (OR 0.06, P=0.075) or >90-day PVT risk (OR 1.23, P=0.466). The strongest predictor of >90-day PVT was cancer recurrence (OR 3.96, P<0.001). CONCLUSIONS: VR increases PVT risk following PD/TP, with technical factors influencing <90-day PVT and cancer-related factors influencing >90-day PVT. The benefits of early postoperative anticoagulation in preventing PVT post-VR remain unclear.
引用
- Labib PL, McKay SC, Perrodin SF, et al. Anticoagulation Practice and Risk of Portal Vein Thrombosis Following Pancreaticoduodenectomy or Total Pancreatectomy with Venous Resection: An International Multicentre Cohort Study. Ann Surg. 2025. PMID: 40996212. doi:10.1097/SLA.0000000000006954
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。